O	0	7	Interim
O	8	16	analysis
O	17	19	of
O	20	23	the
O	24	33	incidence
O	34	36	of
O	37	43	breast
O	44	50	cancer
O	51	53	in
O	54	57	the
O	58	63	Royal
O	64	71	Marsden
O	72	80	Hospital
B-intervention	81	90	tamoxifen
O	91	101	randomised
O	102	117	chemoprevention
O	118	123	trial
O	123	124	.

O	125	134	Tamoxifen
O	134	135	,
O	136	137	a
O	138	142	drug
O	143	147	with
O	148	163	antioestrogenic
O	164	171	effects
O	171	172	,
O	173	175	is
O	176	185	predicted
O	186	188	to
O	189	196	prevent
O	197	200	the
O	201	211	occurrence
O	212	214	of
O	215	221	breast
O	222	228	cancer
O	228	229	.

O	230	232	We
O	233	237	have
O	238	248	undertaken
O	249	250	a
O	251	256	trial
O	257	259	of
O	260	269	tamoxifen
O	270	272	in
O	273	280	healthy
O	281	286	women
O	287	290	who
O	291	294	are
O	295	297	at
O	298	307	increased
O	308	312	risk
O	313	315	of
O	316	322	breast
O	323	329	cancer
O	330	337	because
O	338	340	of
O	341	347	family
O	348	355	history
O	355	356	.

O	357	359	We
O	360	366	report
O	367	368	a
O	369	376	planned
O	377	384	interim
O	385	393	analysis
O	393	394	.

O	395	402	Between
O	403	410	October
O	410	411	,
O	412	416	1986
O	416	417	,
O	418	421	and
O	422	427	April
O	427	428	,
O	429	433	1996
O	433	434	,
O	435	437	we
O	438	445	accrued
B-total-participants	446	450	2494
O	451	458	healthy
O	459	464	women
O	465	469	aged
B-age	470	477	between
I-age	478	480	30
I-age	481	484	and
I-age	485	487	70
B-eligibility	488	492	with
I-eligibility	493	494	a
I-eligibility	495	501	family
I-eligibility	502	509	history
I-eligibility	510	512	of
I-eligibility	513	519	breast
I-eligibility	520	526	cancer
O	526	527	.

O	528	532	They
O	533	537	have
O	538	542	been
O	543	553	randomised
O	554	555	(
O	555	561	double
O	562	567	blind
O	567	568	)
O	569	571	to
O	572	579	receive
O	580	589	tamoxifen
O	590	592	20
O	593	595	mg
O	596	599	per
O	600	603	day
O	604	610	orally
O	611	613	or
B-control	614	621	placebo
O	622	625	for
O	626	628	up
O	629	631	to
O	632	633	8
O	634	639	years
O	639	640	.

O	641	647	Follow
O	647	648	-
O	648	650	up
O	651	659	included
O	660	668	clinical
O	669	679	assessment
O	679	680	,
O	681	687	annual
O	688	699	mammography
O	699	700	,
O	701	704	and
O	705	715	assessment
O	716	718	of
O	719	727	toxicity
O	728	731	and
O	732	742	compliance
O	742	743	.

O	744	747	The
O	748	755	primary
O	756	764	endpoint
O	765	768	was
O	769	772	the
B-outcome-Measure	773	783	occurrence
I-outcome-Measure	784	786	of
I-outcome-Measure	787	793	breast
I-outcome-Measure	794	800	cancer
O	800	801	,
O	802	807	which
O	808	811	was
O	812	820	analysed
O	821	823	on
O	824	826	an
O	827	836	intention
O	836	837	-
O	837	839	to
O	839	840	-
O	840	845	treat
O	846	851	basis
O	852	856	with
O	857	858	a
O	859	867	survival
O	868	873	curve
O	873	874	.

O	875	879	With
O	880	881	a
O	882	888	median
O	889	895	follow
O	895	896	-
O	896	898	up
O	899	901	of
O	902	904	70
O	905	911	months
O	911	912	,
B-total-participants	913	917	2471
O	918	923	women
O	924	925	(
O	925	934	tamoxifen
B-intervention-participants	935	939	1238
O	939	940	,
O	941	948	placebo
B-control-participants	949	953	1233
O	953	954	)
O	955	959	were
O	960	968	suitable
O	969	972	for
O	973	981	analysis
O	981	982	.

O	983	986	The
O	987	993	groups
O	994	998	were
O	999	1005	evenly
O	1006	1013	matched
O	1014	1016	at
O	1017	1025	baseline
O	1025	1026	,
O	1027	1030	and
O	1031	1041	compliance
O	1042	1045	was
O	1046	1050	good
O	1050	1051	.

O	1052	1055	The
B-outcome	1056	1063	overall
I-outcome	1064	1073	frequency
I-outcome	1074	1076	of
I-outcome	1077	1083	breast
I-outcome	1084	1090	cancer
O	1091	1093	is
O	1094	1097	the
O	1098	1102	same
O	1103	1106	for
O	1107	1112	women
O	1113	1115	on
O	1116	1125	tamoxifen
O	1126	1128	or
O	1129	1136	placebo
O	1137	1138	(
O	1138	1147	tamoxifen
B-iv-bin-abs	1148	1150	34
O	1150	1151	,
O	1152	1159	placebo
B-cv-bin-abs	1160	1162	36
O	1162	1163	,
O	1164	1172	relative
O	1173	1177	risk
O	1178	1179	1
O	1179	1180	.
O	1180	1182	06
O	1183	1184	[
O	1184	1186	95
O	1186	1187	%
O	1188	1190	CI
O	1191	1192	0
O	1192	1193	.
O	1193	1194	7
O	1194	1195	-
O	1195	1196	1
O	1196	1197	.
O	1197	1198	7
O	1198	1199	]
O	1199	1200	,
O	1201	1202	p
O	1202	1203	=
O	1203	1204	0
O	1204	1205	.
O	1205	1206	8
O	1206	1207	)
O	1207	1208	.

O	1209	1221	Participants
O	1222	1225	who
O	1226	1230	were
O	1231	1238	already
O	1239	1241	on
O	1242	1249	hormone
O	1249	1250	-
O	1250	1261	replacement
O	1262	1269	therapy
O	1270	1274	when
O	1275	1279	they
O	1280	1287	entered
O	1288	1291	the
O	1292	1297	study
O	1298	1301	had
O	1302	1304	an
O	1305	1314	increased
B-outcome	1315	1319	risk
I-outcome	1320	1322	of
I-outcome	1323	1329	breast
I-outcome	1330	1336	cancer
O	1337	1345	compared
O	1346	1350	with
O	1351	1354	non
O	1354	1355	-
O	1355	1360	users
O	1360	1361	.

O	1362	1367	Those
O	1368	1380	participants
O	1381	1384	who
O	1385	1392	started
O	1393	1397	such
O	1398	1405	therapy
O	1406	1411	while
O	1412	1414	on
O	1415	1420	trial
O	1421	1424	had
O	1425	1426	a
O	1427	1440	significantly
O	1441	1448	reduced
O	1449	1453	risk
O	1453	1454	.

O	1455	1458	The
B-outcome	1459	1465	safety
I-outcome	1466	1473	profile
O	1474	1476	of
O	1477	1486	tamoxifen
O	1487	1490	was
O	1491	1493	as
O	1494	1502	expected
O	1502	1503	.

O	1504	1506	We
O	1507	1511	have
O	1512	1516	been
O	1517	1523	unable
O	1524	1526	to
O	1527	1531	show
O	1532	1535	any
O	1536	1542	effect
O	1543	1545	of
O	1546	1555	tamoxifen
O	1556	1558	on
O	1559	1565	breast
O	1565	1566	-
O	1566	1572	cancer
O	1573	1582	incidence
O	1583	1585	in
O	1586	1593	healthy
O	1594	1599	women
O	1599	1600	,
O	1601	1609	contrary
O	1610	1612	to
O	1613	1616	the
O	1617	1623	report
O	1624	1628	from
O	1629	1632	the
O	1633	1638	NSABP
O	1638	1639	-
O	1639	1641	P1
O	1642	1647	study
O	1648	1655	showing
O	1656	1657	a
O	1658	1660	45
O	1660	1661	%
O	1662	1671	reduction
O	1672	1674	in
O	1675	1682	healthy
O	1683	1688	women
O	1689	1694	given
O	1695	1704	tamoxifen
O	1705	1711	versus
O	1712	1719	placebo
O	1719	1720	.

O	1721	1732	Differences
O	1733	1735	in
O	1736	1739	the
O	1740	1745	study
O	1746	1757	populations
O	1758	1761	for
O	1762	1765	the
O	1766	1769	two
O	1770	1776	trials
O	1777	1780	may
O	1781	1789	underlie
O	1790	1795	these
O	1796	1807	conflicting
O	1808	1816	findings
O	1816	1817	:
O	1818	1829	eligibility
O	1830	1832	in
O	1833	1836	our
O	1837	1842	trial
O	1843	1846	was
O	1847	1852	based
O	1853	1866	predominantly
O	1867	1869	on
O	1870	1871	a
O	1872	1878	strong
O	1879	1885	family
O	1886	1893	history
O	1894	1896	of
O	1897	1903	breast
O	1904	1910	cancer
O	1911	1918	whereas
O	1919	1921	in
O	1922	1925	the
O	1926	1931	NSABP
O	1932	1937	trial
O	1938	1941	was
O	1942	1948	mostly
O	1949	1954	based
O	1955	1957	on
O	1958	1961	non
O	1961	1962	-
O	1962	1969	genetic
O	1970	1974	risk
O	1975	1982	factors
O	1982	1983	.

O	1984	1987	The
O	1988	1998	importance
O	1999	2001	of
O	2002	2011	oestrogen
O	2012	2021	promotion
O	2022	2025	may
O	2026	2030	vary
O	2031	2038	between
O	2039	2043	such
O	2044	2055	populations
O	2055	2056	.
